ProQR Therapeutics NV

ProQR Therapeutics NV

ProQR Therapeutics NV

Overview
Date Founded

2012

Headquarters

Zernikedreef 9,Leiden, Zuid-Holland 2333 CK

Type of Company

Public

Employees (Worldwide)

130

Industries

Pharmaceuticals
Biotechnology

Company Description

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Contact Data
Trying to get in touch with decision makers at ProQR Therapeutics NV? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder, Chief Innovation Officer

Chief Executive Officer

Chief Financial & Business Officer

Chief Medical Officer

Vice President, Head of Commercial

Executive Vice President, Research & Development

Vice President of Investor Relations & Corporate Communications

Director-Corporate Communications

Supervisory Board

Managing Director at Stichting Administratiekantoor Endavit

Chairman at Sofinnova Partners SAS

Former Chief Medical Officer at GlaxoSmithKline Plc

Chief Executive Officer, President & Director at Kaleido Biosciences, Inc.

Former Chief Marketing & Strategy Officer at The British United Provident Association Ltd.

Chief Financial Officer & Chief Operating Officer at Galapagos NV

Paths to ProQR Therapeutics NV
Potential Connections via
Relationship Science
You
ProQR Therapeutics NV
Owners & Shareholders
Details Hidden

RTW Investments employs an event-driven investment strategy that focuses on long/short investments in US healthcare companies. The firm invests primarily in the stocks of: (1) pharmaceutical companies (2) medical device manufacturers and (3) diagnostic tool manufacturers. RTW Investments also makes select investments in derivatives and fixed-income instruments.

Details Hidden

Aquilo Capital Management focuses on long/short investments in the stocks of companies in the life sciences and biotechnology sectors

Details Hidden

SFML is a hands-on manager which aims to maximize returns and preserve capital for clients by primarily investing in listed Israeli companies to create a well-balanced, long-term portfolio.The firm takes a conservative approach to market exposure and leverage, managing risk by implementing a disciplined trading approach, using stop-losses and defined price targets for individual positions. They seek to reduce market risk by using correlated derivatives, shorting market indices, sector ETFs, or specific industry stocks with similar drivers and aim to neutralize currency risk by hedging all non-dollar denominated investments in their portfolio.

Recent Transactions
Details Hidden

ProQR Therapeutics NV issued USD Common Stock

Details Hidden

ProQR Therapeutics NV issued Ordinary Shares

Details Hidden

ProQR Therapeutics NV issued Ordinary Shares

Transaction Advisors
Escrow Agent

Advised onProQR Therapeutics NV issued USD Common Stock

Auditor

Advised onProQR Therapeutics NV issued USD Common Stock

Underwriter

Advised onProQR Therapeutics NV issued USD Common Stock

Associate

Advised onProQR Therapeutics NV issued Ordinary Shares

Managing Director

Advised onProQR Therapeutics NV issued USD Common Stock

Legal Advisor

Advised onProQR Therapeutics NV issued Ordinary Shares

Advisors & Consultants
Special Advisor

Chief Medical Officer at Breath Therapeutics GmbH

Legal Advisor

Attorney at Goodwin Procter LLP

Key Stats and Financials As of 2018
Market Capitalization
$439M
Total Enterprise Value
$424M
Earnings Per Share
$-1.28
Revenue
$0
Net Profit
$-43.5M
EBITDA
$-48.5M
Total Debt
$8.04M
Total Equity
$106M
TEVNet Income
-9.75x
Debt TEV
0.02x
Investors
Details Hidden

Gilde Healthcare Partners BV operates as a venture capital firm that specializes in management buy-outs and growth capital investments in start-up, seed, growth stage, emerging growth, lower middle market, expansion, early, mid, and late stage companies in the healthcare technology and healthcare services sector. It focuses on Healthcare providers and suppliers of goods and services to healthcare providers, biopharma, pharmaceutical, clinical stage therapeutics companies, diagnostics, medical devices, healthcare services including home healthcare services, medical technology, digital healthcare, life sciences, and supporting technologies. The company was founded by Pieter van der Meer and Edwin W. de Graaf in 1999 and is headquartered in Utrecht, the Netherlands

Details Hidden

Sofinnova Partners is an active manager which invests exclusively in life sciences and information technology firms in France, Europe, and to a limited extent, the US. They also have expertise in the clean technology sector. The firm aims to build companies from seed rounds to a trade sale or an IPO, investing in start-ups and early-stage companies with ambitious projects. They prefer to invest in companies capable of attracting European investors, contributing a minimum of 0.5 million euros per investment, and up to 20 million euros over several rounds of financing.Sofinnova Partners acts as lead or co-lead investor, taking a seat on the board of directors and seeking to bring added value to the investee company management team. The firm builds alliances, teaming up with other venture capitalists so that the investee company can cover their future capital needs and expand.In Information Technology, Sofinnova Partners aims to identify new trends and technological breakthroughs in areas such as materials, photonics and micro-electronics, embedded software and user interfaces for wireless and consumer electronics and IT infrastructure software solutions. The firm maintains a best-practice approach, teaming up with experts who combine scientific knowledge and business experience to help in their selection process.In Life Sciences, Sofinnova Partners focuses on ambitious seed and start-up projects developing new therapeutics in biopharmaceuticals and medical devices and give special attention to spin-offs or teams which leave companies in these two sectors, seeking to invest in companies which develop new products for unmet clinical needs, address big markets and which combine entrepreneurial and pharmaceutical experience.

Details Hidden

President at Mossrock Capital LLC

Suppliers
The Massachusetts General Hospital Medical Support Services | Boston, Massachusetts

Since 1811, Massachusetts General Hospital has been committed to delivering standard-setting medical care. Throughout the decades, the hospital has had a consistent commitment to advancing that care through pioneering research and educating future health care professionals. The third oldest general hospital in the United States and the oldest and largest hospital in New England, Mass General continues its tradition of excellence today. On July 17, 2012, Mass General was named America's best hospital by U. S. News & World Report based on our quality of care, patient safety and reputation in 16 different specialties. In 2008, Mass General was redesignated a Magnet hospital, the highest honor for nursing excellence awarded by the American Nurses Credentialing Center. World-Class Patient Care Our 907-bed medical center, located in the heart of Boston, offers sophisticated diagnostic and therapeutic care in virtually every specialty and subspecialty of medicine and surgery. We offer high-quality care and services in four health centers in the Boston area. The hospital also holds concurrent Level 1 verification for adult and pediatric trauma and burn care. Our five multidisciplinary care centers – known worldwide for innovations in cancer, digestive disorders, heart disease, transplantation and vascular medicine – unite specialists across the hospital to offer patients comprehensive, state-of-the-art medical care. In addition, through MassGeneral Hospital for Children, we provide a full range of pediatric health care services, from primary care to cutting-edge treatments of complex and rare disorders. A Research Powerhouse Mass General has long been a leader in successfully bridging innovative science with state-of-the-art clinical medicine. With an annual research budget of nearly $764 million, Mass General conducts the largest hospital-based research program in the United States - a program that spans more than 20 clinical departments and centers across the hospital. This funding drives discoveries and breakthroughs in basic and clinical research, which translate into new and better treatments that transform medical practice and patient care. Learn more about Mass General research. An Emphasis on Teaching Mass General is the original and largest teaching hospital of Harvard Medical School, where nearly all of our staff physicians serve on the faculty. Since the hospital’s founding, Mass General has been committed to training and mentoring the next generation of international leaders in science and medicine, providing a wealth of opportunities for physicians, nurses, allied health professionals, physical, occupational and speech and language therapists and other health professionals. These talented men and women, in turn, lend fresh and innovative perspective on how to treat and care for patients. See medical residency and fellowship opportunities at Mass General. Setting the Bar for Quality & Safety Safety, effectiveness, patient centeredness, timeliness, efficiency and equity – these six tenets established by the Institute of Medicine are the foundation of our approach to quality and safety. We measure our performance, set high goals and track our progress toward those goals. We compare ourselves against local and national benchmarks in key quality and safety areas to ensure we deliver the highest quality and safest care possible. Learn more about our quality and patient-safety programs. Reaching Out to the Community Our work has always been guided by the needs of patients and their families. Mass General partners with communities to build, improve and sustain health care delivery and increase the health and well-being of those who live and work and these communities. Read about how Mass General is making a difference locally and globally. At our main campus and four health centers in Charlestown, Chelsea, Revere and the North End, Mass General annually: Admits 47,000 inpatients Handles nearly 1.4 million outpatient visits Records 88,000 emergency room visits Performs 38,000 operations Delivers 3,600 babies Mass General is a founding member of Partners HealthCare, an integrated health care delivery system that includes the two founding academic medical centers, community hospitals, primary care and specialty physicians, specialty facilities, community health centers and other health-related entities. Our Mission Guided by the needs of our patients and their families, we aim to deliver the very best health care in a safe, compassionate environment; to advance that care through innovative research and education; and to improve the health and well-being of the diverse communities we serve

Leids Universitair Medisch Centrum Hospitals & Patient Services | Leiden, ZH

Leids Universitair Medisch Centrum provides medical research, patient care, training, and education. The firm is a university knowledge center for fundamental medical and applied clinical research. The company was founded in 1996 and is headquartered in Leiden, the Netherlands.

Competitors
University of Southern California Human Resources & Personnel Services - Los Angeles, CA

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

Applied Genetic Technologies Corp. Pharmaceuticals - Alachua, Florida

Applied Genetic Technologies Corp. engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

Amicus Therapeutics, Inc. Pharmaceuticals - Cranbury, New Jersey

Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by ProQR Therapeutics NV. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of ProQR Therapeutics NV's profile does not indicate a business or promotional relationship of any kind between RelSci and ProQR Therapeutics NV.